Your browser doesn't support javascript.
loading
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres, Lauren C; Oswald, Laura B; Dillard, Christen M; De Avila, Gabriel; Nishihori, Taiga; Blue, Brandon J; Freeman, Ciara L; Locke, Frederick L; Alsina, Melissa; Castaneda Puglianini, Omar; Shune, Leyla; Sborov, Douglas W; Wagner, Charlotte; Dima, Danai; Hashmi, Hamza; Davis, James A; Kocoglu, Mehmet H; Badros, Ashraf Z; Atrash, Shebli; Simmons, Gary; Kalariya, Nilesh; Ferreri, Christopher; Anderson, Larry D; Afrough, Aimaz; Kaur, Gurbakhash; Lin, Yi; Liu, Lawrence; Nadeem, Omar; Voorhees, Peter; Khouri, Jack; McGuirk, Joseph; Sidana, Surbhi; Hansen, Doris K; Patel, Krina.
Affiliation
  • Peres LC; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Oswald LB; Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Dillard CM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • De Avila G; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Nishihori T; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Blue BJ; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Freeman CL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Alsina M; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Castaneda Puglianini O; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS.
  • Sborov DW; Division of Hematology and Hematologic Malignancies, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT.
  • Wagner C; Division of Hematology and Hematologic Malignancies, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT.
  • Dima D; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
  • Hashmi H; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, SC.
  • Davis JA; Department of Pharmacy, Medical University of South Carolina, Charleston, SC.
  • Kocoglu MH; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD.
  • Badros AZ; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD.
  • Atrash S; Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC.
  • Simmons G; Cellular Immunotherapies and Transplant Program, Virginia Commonwealth University Massey Cancer Center, Richmond, VA.
  • Kalariya N; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ferreri C; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Anderson LD; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
  • Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
  • Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
  • Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Liu L; City of Hope, Duarte, CA.
  • Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Voorhees P; Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC.
  • Khouri J; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
  • McGuirk J; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS.
  • Sidana S; Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.
  • Hansen DK; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Patel K; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Adv ; 8(1): 251-259, 2024 01 09.
Article in En | MEDLINE | ID: mdl-37855718
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Plasma Cell / Multiple Myeloma Limits: Humans Country/Region as subject: America do norte Language: En Journal: Blood Adv Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Plasma Cell / Multiple Myeloma Limits: Humans Country/Region as subject: America do norte Language: En Journal: Blood Adv Year: 2024 Document type: Article